Effective, pharmacologic approaches to the treatment of
cerebellar ataxia are lacking or inadequate. We recently reported preliminary evidence that
tandospirone citrate (
tandospirone), a
5-HT1A agonist, improved
cerebellar ataxia in patients with
Machado-Joseph disease (MJD). In the course of that study, we found that such treatment also alleviated the
pain associated with cold sensations in the legs,
insomnia,
anorexia, and depression, all of which are thought to be mediated through activation of the
5-HT1A receptor. In this paper, we reviewed the few published clinical trials that involved the use of
5-HT1A receptor agonists for the treatment of
cerebellar ataxia, and discussed the current theories regarding their mechanism of action. Cortical cerebellar
atrophy (CCA) was reported, in a double-blind study, to be amenable to treatment with
tandospirone. Other types of
spinocerebellar degeneration (SCD) i.e.,
olivopontocerebellar atrophy (OPCA) and
Machado-Joseph disease (MJD) have also been reported to respond to the
drug, but these have been small studies. Responsive patients exhibited only mild
ataxia. The doses of 5-HT1A agonists that have been used successfully ranged from 12.5 mg/day to 60 mg/day (or 1 mg/kg), and were well tolerated by most patients.